Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | CFD | P00746 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848357 | 0.86 | ALDH1A1 (0.71) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL230029 | 0.84 | RAB9A (0.50) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL640263 | 0.83 | TSHR (1.00) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL30154503 | 0.83 | TSHR (1.00) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL1147026 | 0.83 | MAPT (0.53) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL8451093 | 0.83 | HTT (0.70) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL10541988 | 0.81 | TSHR (0.96) | TSHRALDH1A1KDM4ERAB9AGAA | |
| Hydrochloric Acid SCHEMBL9650466 | 0.81 | TSHR (0.96) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL31493230 | 0.81 | HTT (1.00) | TSHRALDH1A1KDM4ERAB9AGAA | |
| SCHEMBL503994 | 0.81 | HTT (1.00) | TSHRALDH1A1KDM4ERAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874632-B1 | TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY | SPHAERA PHARMA PTE LTD (SG) | 2020-06-17 | — | — | EP | disclosed |
| US-10329266-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2019-06-25 | — | — | US | disclosed |
| US-20180327371-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2018-11-15 | — | — | US | disclosed |
| US-20170334867-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2014016849-A9 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2014-03-13 | — | — | WO | disclosed |
| EP-2331548-B1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2013-09-04 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| EP-0737733-A1 | Liquid crystal compound having ferrielectric phase and liquid crystal composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1996-10-16 | — | — | EP | disclosed |
| EP-0718274-A1 | Two-rings-containing phenyl ester compound and anti-ferroelectric liquid crystal composition containing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1996-06-26 | — | — | EP | disclosed |
| EP-0559088-B1 | Dioxane type liquid crystal substance | MITSUBISHI GAS CHEMICAL CO (JP) | 1996-05-15 | — | — | EP | disclosed |
| US-5482651-A | ANTIFERROELECTRIC | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1996-01-09 | — | — | US | disclosed |
| EP-0418922-B1 | Mesomorphic compound, liquid crystal composition containing same and liquid crystal device using same | CANON KK (JP) | 1995-04-12 | — | — | EP | disclosed |
| US-5364560-A | Liquid crystal compound and liquid crystal display device | MITSUBISHI GAS CHEMICAL CO., INC. (JP) | 1994-11-15 | — | — | US | disclosed |
| EP-0559088-A1 | Dioxane type liquid crystal substance | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1993-09-08 | — | — | EP | disclosed |
| US-5200109-A | 4-substituted-3-fluorophenyl-thiadiazole derivatives; high speed responsiveness, heat resistance, displaying | CANON KABUSHIKI KAISHA (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0497297-A2 | Liquid crystal compound and liquid crystal display device | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0418922-A2 | Mesomorphic compound, liquid crystal composition containing same and liquid crystal device using same | CANON KABUSHIKI KAISHA (JP) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329266-B2 | Protease inhibitors | CTSK, CTSF, CTSS | TSHR 1000/4885ALDH1A1 3140/4885KDM4E 3773/4885 |
| US-20170334867-A1 | PROTEASE INHIBITORS | CTSK, MMP26, MMP3 | TSHR 1092/4885ALDH1A1 3144/4885KDM4E 3966/4885 |
| US-20180327371-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | TSHR 1000/4885ALDH1A1 3140/4885KDM4E 3773/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | TSHR 3086/4885ALDH1A1 3488/4885KDM4E 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.